Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration.
Yifan Zhou,Yusra B. Medik,Bhakti Patel,Daniel B. Zamler,Sijie Chen,Thomas Chapman,Sarah Schneider,Rachel L. Babcock,Taylor T. Chrisikos,Laura M. Kahn,Allison M. Dyevoich,Elizabeth M. Park,Alexandria P. Cogdill,Daniel H. Johnson,Sarah B. Johnson,Khalida M. Wani,Debora A. Ledesma,Courtney W. Hudgens,Jingjing Wang,Md Abdul Wadud Khan,Aron Y. Joon,Weiyi Peng,Haiyan S. Li,Reetakshi Arora,Ximing Tang,Maria Gabriela Raso,Xuegong Zhang,Wai Chin Foo,Michael T. Tetzlaff,Gretchen E. Diehl,Karen Clise-Dwyer,Elizabeth M. Whitley,Matthew M. Gubin,James P. Allison,Patrick Hwu,Nadim J. Ajami,Adi Diab,Jennifer A. Wargo,Stephanie S. Watowich
DOI: https://doi.org/10.1158/1538-7445.am2022-5545
IF: 11.2
2022-01-01
Cancer Research
Abstract:Abstract Immunotherapies such as anti-CTLA-4 immune checkpoint blockade (ICB) have revolutionized cancer treatment, yet quality of life and continuation of therapy can be constrained by off-target tissue damage or immune-related adverse events (irAEs). At present, there is limited understanding of irAE mechanisms, hampering development of approaches to mitigate their damage. We addressed this problem by generating animal models of intestinal irAE. Our results show that disruption of homeostatic immunity by genetic predisposition to intestinal inflammation or acute gastrointestinal infection sensitizes mice to anti-CTLA-4-mediated intestinal toxicity. Inflammation-prone mice treated with anti-CTLA-4 showed neutrophil accumulation, systemic interleukin-6 (IL-6) release, and dysbiosis. Significantly, IL-6 blockade combined with antibiotic treatment improved anti-CTLA-4 therapeutic efficacy and reduced intestinal irAEs. Immune signatures were validated in biopsies from patients who developed colitis during ICB, supporting the utility of our models. This study provides new pre-clinical models, mechanistic insight into irAEs, and potential approaches to enhance ICB efficacy while mitigating irAEs. Citation Format: Yifan Zhou, Yusra B. Medik, Bhakti Patel, Daniel B. Zamler, Sijie Chen, Thomas Chapman, Sarah Schneider, Rachel L. Babcock, Taylor T. Chrisikos, Laura M. Kahn, Allison M. Dyevoich, Elizabeth M. Park, Alexandria P. Cogdill, Daniel H. Johnson, Sarah B. Johnson, Khalida M. Wani, Debora A. Ledesma, Courtney W. Hudgens, Jingjing Wang, Md Abdul Wadud Khan, Aron Y. Joon, Weiyi Peng, Haiyan S. Li, Reetakshi Arora, Ximing Tang, Maria Gabriela Raso, Xuegong Zhang, Wai Chin Foo, Michael T. Tetzlaff, Gretchen E. Diehl, Karen Clise-Dwyer, Elizabeth M. Whitley, Matthew M. Gubin, James P. Allison, Patrick Hwu, Nadim J. Ajami, Adi Diab, Jennifer A. Wargo, Stephanie S. Watowich. Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5545.